Nikol Agadzhanian

Ms. Nikol Agadzhanian


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2022 in Molecules
Verified
Journal Article
Open access
PDF file
STSergei Tsymbal
Sergei Tsymbal
Ge LiGe Li
Ge Li
NANikol Agadzhanian
Nikol Agadzhanian
YSYuhao Sun
Yuhao Sun
JZJiazhennan Zhang
Jiazhennan Zhang
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
Treatment of drug-resistant forms of cancer requires consideration of their hallmark features, such as abnormal cell death mechanisms or mutations in drug-responding molecular pathways. Malignant cells differ from their normal counterparts in numerous aspects, including copper metabolism. Intracellular copper levels are elevated in various cancer types, and this phenomenon could be employed for the development of novel oncotherapeutic approaches. Copper maintains the cell oxidation levels, regulates the protein activity and metabolism, and is involved in inflammation. Various copper-based compounds, such as nanoparticles or metal-based organic complexes, show specific activity against cancer cells according to preclinical studies. Herein, we summarize the major principles of copper metabolism in cancer cells and its potential in cancer theranostics.

1 November 2021 in Biomedicines
Verified
Journal Article
Open access
PDF file
NYNatalia Mikhailovna Yudintceva
Natalia Mikhailovna Yudintceva
ELEkaterina Lomert
Ekaterina Lomert
NMNatalia Arkadyevna Mikhailova
Natalia Arkadyevna Mikhailova
ETElena Tolkunova
Elena Tolkunova
NANikol Agadzhanian
Nikol Agadzhanian
Maxim ShevtsovMaxim Shevtsov
Maxim Shevtsov
Despite multimodal approaches for the treatment of multiforme glioblastoma (GBM) advances in outcome have been very modest indicating the necessity of novel diagnostic and therapeutic strategies. Currently, mesenchymal stem cells (MSCs) represent a promising platform for cell-based cancer therapies because of their tumor-tropism, low immunogenicity, easy accessibility, isolation procedure, and culturing. In the present study, we assessed the tumor-tropism and biodistribution of the superparamagnetic iron oxide nanoparticle (SPION)-labeled MSCs in the orthotopic model of C6 glioblastoma in Wistar rats. As shown in in vitro studies employing confocal microscopy, high-content quantitative image cytometer, and xCelligence system MSCs exhibit a high migratory capacity towards C6 glioblastoma cells. Intravenous administration of SPION-labeled MSCs in vivo resulted in intratumoral accumulation of the tagged cells in the tumor tissues that in turn significantly enhanced the contrast of the tumor when high-field magnetic resonance imaging was performed. Subsequent biodistribution studies employing highly sensitive nonlinear magnetic response measurements (NLR-M2) supported by histological analysis confirm the retention of MSCs in the glioblastoma. In conclusion, MSCs due to their tumor-tropism could be employed as a drug-delivery platform for future theranostic approaches.